Semler Research Centre Pvt Ltd (SRC), a contract research organisation and subsidiary of the US-based Semler Group, today announced that it will invest an additional $10 million in its unit in Bangalore over the next three years. Till now it has invested $10 million in the last three years for drug evaluation and pharmacology research in Bangalore.
Meanwhile, the firm will increase its headcount to 500 from the existing 150 people in the next two years.
The facility is equipped with three clinical pharmacology units with an 80-bed facility to cater to both early and late phase drug development as well as life cycle chain management. The company presently has a formulation development centre in Bangalore and a 48-bed clinical research unit in Salem.
Speaking on the occasion, Krathish Bopanna, executive director and president, SRC said, “The expansion will give SRC an opportunity to unite the world of pharmaceutical research across the globe and enable us to complete the loop in the drug development cycle by providing easy access for early stage research in India. We may expand to contribute towards further evolution of the Indian contract research and development industry.”
The company also envisages enormous potential in biometric space where it hope to delve further through inorganic growth strategies, he added.
On the company, Ronald Semler, chairman, SRC said, “The parent company Semler Group which is into telecom and defence equipment entered into pharma services in India because of the thriving generic industry, the emerging new drug development capabilities and the IT talent pool available for data management.”
India is said to have the highest number of USFDA plants outside the US. Further, India is now a hub for Contract Research and Manufacturing Services (CRAMS) and clinical trials with dependable quality standards, according to the company
